Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
October 02, 2023 13:17 ET
|
Praxis Precision Medicines, Inc.
Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for...
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing
September 20, 2022 08:30 ET
|
Praxis Precision Medicines, Inc.
SAN FRANCISCO and BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from...
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
April 30, 2021 09:00 ET
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines Partners With Ciitizen to Improve Patient-Guided Drug Development
February 16, 2021 09:00 ET
|
Praxis Precision Medicines, Inc
Innovative collaboration to be implemented across multiple indications starting with SCN2A-DEE CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:...